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Abstract
Background: Antimicrobial resistance is an increasing concern in ICUs worldwide. Infection with an antibiotic
resistant (ABR) strain of an organism is associated with greater mortality than infection with the non-resistant strain, but
there are few data assessing whether being admitted to an intensive care unit (ICU) with high levels of antimicrobial
resistance is associated with a worse outcome than being admitted to an ICU with low rates of resistance. The aim of
this study was, therefore, to compare the characteristics of infections and antibiotic treatments and patient outcomes
in patients admitted to ICUs in countries considered as having high levels of antibiotic resistance and those admitted
to ICUs in countries considered as having low levels of antibiotic resistance.
Methods: Data from the large, international EPIC II one-day point prevalence study on infections in patients hospitalized
in ICUs were used. For the current study, we compared the data obtained from patients from two groups of countries:
countries with reported MRSA rates of≥ 25% (highABR: Greece, Israel, Italy, Malta, Portugal, Spain, and Turkey) and
countries with MRSA rates of < 5% (lowABR: Denmark, Finland, Netherlands, Norway, and Sweden).
Results: On the study day, 1187/2204 (53.9%) patients in the HighABR ICUs were infected and 255/558 (45.7%) in the
LowABR ICUs (P < 0.01). Patients in the HighABR ICUs were more severely ill than those in the LowABR ICUs, as reflected
by a higher SAPS II score (35.6 vs 32.7, P < 0.05) and had longer median ICU (12 days vs 5 days) and hospital (24 days vs
16 days) lengths of stay. They also had higher crude ICU (20.0% vs 15.4%) and hospital (27.0% vs 21.5%) mortality rates
(both P < 0.05). However, after multivariable adjustment and matched pair analysis there were no differences in ICU or
hospital mortality rates between High or LowABR ICU patients overall or among those with infections.
Conclusions: Being hospitalized in an ICU in a region with high levels of antimicrobial resistance is not associated per se
with a worse outcome.
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Background
The prevalence of infection is high among patients admit-
ted to ICUs and is one of the main causes of ICU mortality
[1,2]. In 1992, a one-day European point-prevalence study
on infections in intensive care (EPIC), performed in 1417
ICUs in 17 Western European countries [3], showed that
approximately 45% of all patients present on the ICU on
the study day were infected. The mean prevalence of ICU-
acquired infections was 21%, but varied widely from 10% in
Switzerland to 32% in Italy [3]. EPIC II was conducted 15
years later, on May 8, 2007 [2]. Data were collected from
13796 adult (>18 years) patients from 1265 ICUs in 75
countries and showed that 51% of patients had at least one
infection.
Antimicrobial resistance is an increasing concern in
ICUs worldwide. Rates of resistance vary considerably
across different countries and regions; for example, ICUs
in southern Europe generally have higher rates of resist-
ance than countries in northern Europe and Scandinavia
[4]. Several studies have reported that infection with an
antibiotic resistant strain of an organism is associated
with greater mortality and costs and longer ICU lengths
of stay than infection with the non-resistant strain [5-9].
An important question is whether being admitted to an
ICU with high levels of antimicrobial resistance is asso-
ciated with a worse outcome than being admitted to an
ICU with low rates of resistance, but there are few data
available on this topic. In the present study, therefore,
we used data from the large EPIC II study [2] to com-
pare the characteristics of infections, antibiotic treat-
ments and patient outcomes in patients admitted to
ICUs in countries considered as having high levels of
antibiotic resistance, as recorded in the Antimicrobial
Resistance Surveillance System (EARSS) 2007 Annual
Report, and those admitted to ICUs in countries consid-
ered as having low levels of antibiotic resistance. We hy-
pothesized that there would be a difference in outcomes
in patients admitted to ICUs in countries with high
levels of antimicrobial resistance compared to those ad-
mitted to ICUs in countries with low levels of resistance.
Methods
The worldwide EPIC II 1-day point-prevalence study of
infection and demographics of critically ill patients was
performed on 8 May 2007 [2]. Data were collected for
13,796 adult patients in 1265 participating ICUs from 75
countries on the study day. Infection was defined ac-
cording to the criteria of the International Sepsis Forum
[10]. Microbiological analyses were performed locally.
Participating ICUs were asked to provide patient follow-
up until hospital discharge or for 60 days.
For the purposes of this analysis, we selected two groups
of countries based on the country rate of methicillin-
resistant Staphylococcus aureus (MRSA) reported in the
European Antimicrobial Resistance Surveillance System
(EARSS) 2007 Annual Report [11]: countries with MRSA
rates of ≥ 25% in the 2007 report (Greece, Israel, Italy,
Malta, Portugal, Spain, and Turkey) and countries with
MRSA rates of < 5% (Denmark, Finland, Netherlands,
Norway, and Sweden) (see Appendix for list of participat-
ing centres in these countries). Severity scores, source of
infection, pathogens, antibiotic resistance, antibiotic ther-
apy (prophylactic and therapeutic, as defined by the at-
tending physician at each centre), co-morbidities, lengths
of stay and outcomes were compared in patients in the
two groups of countries.
The EPIC II study was approved by the ethics committee
of Erasme Hospital, Belgium, the coordinating center. Local
ethical committee approval at each participating center
(see Appendix for list of participating centers) was expe-
dited or waived because of the observational nature of the
study.
Statistical analyses
Statistical analyses were performed using IBM SPSS Sta-
tistics 20 for Windows (IBM, Armonk, NY, USA). The
Kolmogorov-Smirnov test was used, and histograms and
Q-Q plots were examined to verify if there were signifi-
cant deviations from the normality assumption of con-
tinuous variables. Difference testing between groups was
performed using Mann-Whitney test, χ2 test, or Fisher’s
exact test as appropriate. Logistic regression analysis was
used to determine the mortality risk associated with ad-
mission to an ICU in a country with high levels of anti-
microbial resistance or one with low levels of antimicrobial
resistance. To remove any bias of confounding variables for
the association between the areas of ICU admission and
mortality, a propensity score was estimated for each of the
ICU areas, with the following variables considered as fac-
tors: type of admission, source of admission, comorbidities,
age, sex, mechanical ventilation, haemofiltration or haemo-
dialysis, infection, SAPS II score and type of microorgan-
ism. After checking that balance on all covariates that were
used in the propensity model had been achieved, odds ra-
tios with mortality as the dependent variable were esti-
mated by logistic regression using two strategies: by
matching and by introducing the propensity score in the
model [12,13]. Reported odds ratios were adjusted for pro-
pensity score, hospital and organizational related factors, in-
cluding type of ICU (closed vs. open, community vs.
university, surgical vs. medical), number of ICU beds, num-
ber of nurses, number of physiotherapists, presence of 24-h
ICU physician coverage, length of ICU stay prior to study
day, percentage of gross domestic product spent on health
care generated using the World Health Organization Statis-
tical Information System (based on data from 2006 [14])
and geographical region. Data are presented as median
[interquartile range (IQR)] or number (%), as appropriate.
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Table 1 Characteristics of study population and participating units
Characteristics LowABR countries HighABR countries p-value
Of ICUs N = 54 N = 231
Staffed ICU beds, n (%)
<7 14 (25.9) 67 (29.0) 0.9
7-14 30 (55.6) 122 (52.8)
15+ 10 (18.5) 42 (18.2)
Nurse:patient, n (%)
>1:1 19 (35.2) 16 (6.9) <0.001
1:1-1:1.49 14 (25.9) 42 (18.2)
1:1.5-1:1.99 18 (33.3) 78 (33.8)
<1:2 3 (5.6) 95 (41.1)
24-hr in-house intensivist 48 (88.9) 231 (100%) <0.001
Of patients N = 558 N = 2204
Age, median (25-75 percentile) 65 (53-74) 65 (51-74) 0.574
SAPS II score, median (25-75 percentile) 31 (25-39) 34 (26-44) <0.001
SOFA score, median (25-75 percentile) 5 (3-8) 5 (3-8) 0.806
Length of stay in days in ICU prior to study day, median (25-75 percentile) 1 (0-6) 4 (0-14) <0.001
Infected 255 (45.7) 1187 (53.9) 0.001
Type of admission, n (%) Surgical, elective 203 (36.5) 455 (20.7) <0.001
Surgical, emergency 200 (36.0) 952 (43.2)
Medical 114 (20.5) 534 (24.3)
Trauma 39 (7.0) 261 (11.9)
Admission source, n (%) OR/recovery 205 (37.7) 472 (21.5) < 0.001
ED/ambulance 111 (20.4) 680 (31.0)
Hospital ward 160 (29.4) 713 (32.5)
Other hospital 61 (11.2) 273 (12.4)
Other 7 (1.3) 55 (2.5)
Main reason for admission, n (%) Surveillance/monitoring 158 (28.3) 336 (15.2) < 0.001
Neurological 56 (10.0) 350 (15.9)
Respiratory 119 (21.3) 527 (23.9)
Cardiovascular 119 (21.3) 579 (26.3)
Renal 5 (0.9) 33 (1.5)
Digestive/liver 53 (9.5) 154 (7.0)
Trauma 36 (6.5) 198 (9.0)
Other 12 (2.2) 27 (1.2)
Co-morbidities, n (%) COPD 77 (13.8) 457 (20.7) <0.001
Haematological cancer 11 (2.0) 49 (2.2) 0.715
Cancer 82 (14.7) 341 (15.5) 0.649
IDDM 42 (7.5) 221 (10.0) 0.072
Heart Failure (NYHA III-IV) 59 (10.6) 231 (10.5) 0.949
CRF 14 (2.5) 165 (7.5) <0.001
HIV 2 (0.4) 15 (0.7) 0.385
Cirrhosis 14 (2.5) 65 (2.9) 0.577
Immunosuppression 24 (4.3) 95 (4.3) 0.992
Number of co-morbidities, n (%) None 282 (50.5) 1011 (45.9) 0.029
1 195 (34.9) 746 (33.8)
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All tests were two-tailed, and a P < 0.05 was considered sta-
tistically significant.
Results
In the EPIC II database, there were 2204 patients included
from ICUs in countries with high levels of antimicrobial
resistance (HighABR) according to the EARSS 2007 An-
nual Report [11] and 558 from ICUs in countries with low
levels of antimicrobial resistance (LowABR) Table 1). The
median SAPS II score was significantly higher in HighABR
than in LowABR ICU patients (34 [26-44] vs 31 [25-39]
P < 0.001) and chronic renal failure and chronic obstruct-
ive pulmonary disease (COPD) were significantly more
common (Table 1). Patients from HighABR ICUs were
more often admitted from the emergency room and less
often from the operating/recovery room than were pa-
tients from LowABR ICUs. Patients from HighABR ICUs
had longer ICU and hospital lengths of stay than patients
from LowABR ICUs; the number of days in the ICU prior
to the study day was also longer in patients admitted to
HighABR ICUs (Table 1).
Infections and Microbiology
More patients in the HighABR ICUs than in the Low-
ABR ICUs were infected on the study day (53.9% vs
45.7%, P < 0.01). The respiratory system was the most
common site of infection in all patients (Additional file 1).
The sites of infection were similar in the two groups ex-
cept for abdominal infections, which were more common
in patients admitted to LowABR ICUs (24.3% vs 18.4%, P
= 0.03), and bloodstream infections, which were more
common in patients admitted to HighABR ICUs (19.6% vs
16.1%, P = 0.03). Culture specimens were positive in 852
(71.8%) of the patients from HighABR ICUs and in 196
(76.9%) of the patients from LowABR ICUs (P =NS). As
expected, MRSA was more common in patients in the
HighABR ICUs than those in the LowABR ICUs (69/137
[50%] vs 2/32 [6%], P < 0.001) (Table 2). Infections caused
by Pseudomonas aeruginosa or Actinetobacter were signifi-
cantly more prevalent among HighABR ICU patients
(Table 2), whereas methicillin-sensitive S. aureus (MSSA),




Use of therapeutic antimicrobials was significantly more
common overall in HighABR ICU patients than in
Table 1 Characteristics of study population and participating units (Continued)
2 61 (10.9) 313 (14.2)
3 16 (2.9) 103 (4.7)
>3 4 (0.7) 31 (1.4)
Treatments, n (%) Mechanical ventilation 359 (64.7) 1388 (63.1) 0.502
Haemofiltration or haemodialysis 47 (8.5) 171 (7.8) 0.591
Length of stay, median (25-75 percentile) ICU 5 (1-19) 12 (3-31) < 0.001
Hospital 16 (7-37) 24 (10-54) <0.001
Mortality ICU 83 (15.4) 408 (20.0) 0.016
Hospital 116 (21.5) 551 (27.0) 0.01
OR, operating room; ED, emergency department; COPD, chronic obstructive pulmonary disease; IDDM, insulin-dependent diabetes mellitus; NYHA III-IV, New York
Heart Association class III-IV; CRF, chronic renal failure; HIV, human immunodeficiency virus.









S. aureus 32 (16.3) 137 (16.1) 0.993
MRSA 2 (1.0) 69 (8.1) <0.001
MSSA 30 (15.3) 70 (8.2) 0.002
S. epidermidis 18 (9.2) 117 (13.7) 0.087
S. pneumoniae 14 (7.1) 39 (4.6) 0.139
Enterococci 31 (15.8) 92 (10.8) 0.049
G+, others 20 (10.2) 48 (5.6) 0.019
E. coli 36 (18.4) 128 (15.0) 0.245
Enterobacteriaceae 10 (5.1) 52 (6.1) 0.592
Klebsiella 21 (10.7) 92 (10.8) 0.973
P. aeruginosa 27 (13.8) 172 (20.2) 0.039
Acinetobacter spp 5 (2.6) 130 (15.3) <0.001
ESBL-producing 4 (2.0) 10 (1.2) 0.340
G−, others 37 (18.9) 136 (16.0) 0.322
Anaerobes 15 (7.7) 22 (2.6) <0.001
Bacteria, others 3 (1.5) 12 (1.4) 0.897
Candida 45 (23.0) 156 (18.3) 0.136
Aspergillus 1 (0.5) 8 (0.9) 0.557
Fungi, others 5 (2.6) 6 (0.7) 0.022
Parasites 4 (2.0) 6 (0.7) 0.083
Organisms, others 12 (6.1) 19 (2.2) 0.004
MRSA, methicillin-resistant S. aureus; MSSA, methicillin-sensitive S. aurues; G+,
Gram positive; ESBL, extended-spectrum-beta-lactamase; G-, Gram negative.
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LowABR ICU patients (54.6% vs 44.4%, P < 0.001). When
considering groups of antimicrobials, carbapenems, ami-
noglycosides, quinolones and glycopeptides were more
commonly used in patients in HighABR ICUs than in
LowABR ICUs, whereas cephalosporins were used more
frequently as treatment in LowABR ICUs (Table 3). For
individual antimicrobials, piperacillin-tazobactam, imipe-
nem/meropenem, amikacin, oxazolidinone and tigecycline
were used more frequently in patients in HighABR ICUs;
cefazolin, cefuroxime, benzylpenicillin, oxa-/cloxa-/flu-
cloxacillin, erythromycin and metronidazole were used
more frequently in patients in LowABR ICUs (Table 3).
Prophylaxis
Use of prophylactic antimicrobials was significantly less
common in HighABR ICU patients than in LowABR
ICU patients (22.2% vs 32.8%, P < 0.001). Among the
agents most commonly used were aminoglycosides
(tobramycin), antifungals (amphotericin B) and cepha-
losporins (Additional file 2).
Mortality
Crude ICU (20.0% and 15.4%) and hospital (27.0% vs
21.5%) mortality rates were higher in patients admitted
to HighABR than in those admitted to LowABR ICUs
(both P < 0.05); however, these differences were not
present after adjustment in multivariable analysis or the
matched pair analysis (Table 4). For subgroups of in-
fected or non-infected patients there were no significant
differences in crude or adjusted mortality rates between
HighABR and LowABR ICUs.
Patients with infections due to Pseudomonas aerugi-
nosa had crude ICU and hospital mortality rates of
32.4% and 42.7%, respectively. Corresponding percent-
ages for patients with Acinetobacter infections were 31.7
and 37.3, respectively, and for MRSA 32.3 and 43.1, re-
spectively. Because of the relatively small sample sizes,
we were unable to compare outcomes for the different
pathogens in the two groups.






(n = 255) (n = 1187)
Antimicrobial, n (%)
Cephalosporins (all) 84 (32.9) 206 (17.4) <0.001
Cefazolin 4 (1.6) 4 (0.3) 0.016
Cefuroxime 46 (18.0) 2 (0.2) <0.001
Ceftazidime 8 (3.1) 40 (3.4) 0.851
Cefepime/Cefpirome 1 (0.4) 24 (2.0) 0.070
Other cephalosporins 26 (10.2) 139 (11.7) 0.491
Penicillins (all) 84 (32.9) 400 (33.7) 0.816
Benzylpenicillin 16 (6.3) 3 (0.3) <0.001
Ampicillin 5 (2.0) 29 (2.4) 0.645
Amoxycillin +
Clavulanic acid
16 (6.3) 71 (6.0) 0.858
Piperacillin +
Tazobactam
27 (10.6) 273 (23.0) <0.001
Oxa-/Cloxa-/
Flucloxacillin
14 (5.5) 16 (1.3) <0.001
Other penicillins 8 (3.1) 20 (1.7) 0.127
Other β-lactams (all) 44 (17.3) 381 (32.1) <0.001
Imipenem/
meropenem
44 (17.3) 365 (30.7) <0.001
Aztreonam 0 (0.0) 13 (1.1) 0.093
Unspecified
beta-lactams
0 (0.0) 7 (0.6) 0.219
Aminoglycosides (all) 17 (6.7) 202 (17.0) <0.001
Amikacin 0 (0.0) 114 (9.6) <0.001
Tobramycin 11 (4.3) 26 (2.2) 0.052
Other
aminoglycosides
6 (2.4) 66 (5.6) <0.001
Quinolones (all) 38 (14.9) 242 (20.4) 0.045
Ciprofloxacin 31 (12.2) 128 (10.8) 0.525
Other quinolones 7 (2.7) 114 (9.7) <0.001
Glycopeptides (all) 30 (11.8) 272 (22.9) <0.001
Vancomycin 30 (11.8) 193 (16.3) 0.072
Other glycopeptides 0 (0.0) 81 (6.8) <0.001
Macrolides (all) 13 (5.1) 48 (4.0) 0.448
Erythromycin 6 (2.4) 4 (0.3) <0.001
Other macrolides 7 (2.7) 44 (3.7) 0.451
Other antibiotics (all) 55 (21.6) 321 (27.0) 0.071
Metronidazole 36 (14.1) 71 (6.0) <0.001
Cotrimoxazole 5 (2.0) 30 (2.5) 0.594
Oxazolidinone 0 (0.0) 128 (10.8) <0.001
Tigecycline 0 (0.0) 21 (1.8) 0.032
Unspecified 19 (7.5) 130 (11.0) 0.096
Antifungals (all) 52 (20.4) 209 (17.6) 0.295
Table 3 Use of antimicrobials as treatment in infected
patients (Continued)
Fluconazole 31 (12.2) 110 (9.3) 0.159
Amphotericin B 4 (1.6) 18 (1.5) 0.951
Amphotericin lipid
complex
3 (1.2) 21 (1.8) 0.502
Caspofungin 12 (4.7) 40 (3.4) 0.299
Voriconazole 1 (0.4) 31 (2.6) 0.029
Other antifungals 1 (0.4) 2 (0.2) 0.477
Antivirals (all) 3 (1.2) 22 (1.9) 0.452
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Discussion
The main message of this study is that hospitalization in
an ICU in a country with high levels of antimicrobial re-
sistance is not an independent risk factor for worse out-
come. We chose to select countries with likely high and
low antimicrobial resistance using reported MRSA rates,
although acknowledge that general resistance rates may
have been different; nevertheless, most countries with
high MRSA rates do seem to have high resistance levels
among other organisms [11]. Several studies have shown
increased mortality rates in patients with MRSA infec-
tions compared to those with MSSA infections [15,16].
In an earlier analysis of the EPIC II database, MRSA infec-
tion was associated with an increased risk of death com-
pared to MSSA infection (OR 1.46 [95% CI 1.03-2.06],
P = 0.03) [17]. Using data from the European Antimicrobial
Resistance Surveillance System and the Burden of Resist-
ance and Disease in European Nations project, De Kraker
et al. [15] reported that 27,711 episodes of MRSA blood
stream infections (BSIs) were associated with 5,503 excess
deaths. The same authors compared two prospective co-
horts of patients from 13 ICUs in 13 European countries,
one with MRSA and one with MSSA BSIs, each matched
with control patients without the respective BSI [16].
MRSA and MSSA patients had higher 30-day and hospital
mortality than the control patients, and MRSA patients had
greater 30-day mortality (OR 1.8, P = 0.04) than MSSA pa-
tients. Other studies have reported similar mortality rates
in MRSA and MSSA patients, but longer lengths of stays
and higher associated costs [6,7,18].
Infections due to difficult to treat pathogens, i.e.,
P. aeruginosa, Acinetobacter spp and MRSA, were in
general associated with higher crude ICU and hospital
mortality rates in our study than other infections and
were significantly more prevalent in HighABR ICUs;
however, because of small sample sizes, comparisons be-
tween groups were not possible. We know from other
ICU studies that these pathogens are associated with in-
creased attributable mortality if empirical treatment is
not appropriate [19-21]. Unfortunately, we are unable to
determine whether or not treatment was appropriate in
our study, although we did show that broadspectrum anti-
biotics, such as carbapenems, piperacillin-tazobactam,
amikacin, tigecycline, oxazolidinone and vancomycin,
were more commonly used for treatment in the HighABR
ICUs. Similarly, we did not record antibiograms for the
different species and have no data on rates of resistance,
except for S. aureus and ESBL-producing Gram-negative
bacteria. Infections caused by enterococci and anaerobes
were more common in LowABR ICU patients which may
explain the more frequent abdominal infections and use
of metronidazole in these ICUs.
Conclusions
Infections were more prevalent among patients admitted
to ICUs in HighABR countries than in LowABR coun-
tries. Antibiotic therapy differed markedly, with broader
spectrum antimicrobials being used more frequently in
HighABR countries. ICU patients in HighABR countries
were sicker and had longer ICU and hospital stays and
higher crude ICU and hospital mortality rates, which
could have a marked economical impact; however, after
multivariate adjustment there were no differences in
ICU or hospital mortality rates between the two groups
of patients.
Appendix: List of participating centres for this
EPIC II substudy by country, alphabetically
Denmark: Århus University Hospital (H Betsch); Næstved
Hospital (B Fogh); Rigshospitalet (K Espersen); Sygehus
Fyn (K Jacobsen); Vejle Sygehus (P Berezowicz); Finland:
Helsinki University Central Hospital (V Harjola); Greece:
Ahepa University Hospital (E Sofianos); Athens University
Medical School (A Armaganidis); Evangelismos Hospital
(C Routsi); G.Papanikolaou (M Bitzani); General Hospital
of Rethymno (A Chalkiadaki); Henry Dunant Hospital
(A Michalopoulos); Hippokrateion Hospital Thessaloniki
(E Mouloudi); Kat General Hospital (E Ioannidou); Kat
Table 4 Crude and adjusted odds ratios* (95% CI) for ICU and hospital mortality in the whole cohort and in infected
patients
OR (95% CI) P-value m-OR (95% CI) P-value a-OR (95% CI) P-value
ICU mortality (all) 1.37 (1.06-1.78) 0.016 1.14 (0.76-1.73) 0.526 1.07 (0.78-1.48) 0.661
Hospital mortality (all) 1.35 (1.07-1.69) 0.01 1.07 (0.74-1.55) 0.707 1.12 (0.84-1.48) 0.445
ICU mortality (infected) 1.23 (0.88-1.72) 0.222 1.23 (0.73-2.09) 0.438 0.99 (0.66-1.49) 0.95
Hospital mortality (infected) 1.21 (0.89-1.63) 0.218 1.02 (0.63-1.65) 0.933 1.1 (0.77-1.58) 0.606
ICU mortality (not infected) 1.38 (0.91-2.09) 0.131 1.01 (0.5-2.02) 0.984 1.32 (0.78-2.22) 0.304
Hospital mortality (not infected) 1.33 (0.93-1.92) 0.121 1.16 (0.64-2.11) 0.629 1.19 (0.75-1.9) 0.461
OR: Odds ratio; m-OR: Odds ratio from matched-pairs. a-OR: adjusted odds ratio. *With admission to HighABR ICU as the reference category. The list of
confounders included in the multivariable analysis is reported in the text.
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Hospital (P Myrianthefs); Kat Hospital, Athens (D
Koulenti); Konstantopoulio General Hospital (I Karampela);
Lamia General Hospital (G Kyriazopoulos); Red
Cross Hospital of Athens (K Mandragos); Thriassio
Hospital of Eleusis (P Clouva-molyvdas); University
Hospital of Ioannina (A Moraiti); University Hospital
of Alexandroupolis (I Pneumatikos); University Hospital
of Rion, Patras (K Filos); University Hospital of Thessaly
(Larissa) (E Zakynthinos); University of Athens, Medical
Shcool (A Kotanidou); Xanthi General Hospital (A
Vakalos); Israel: Hadassah Medical Center (C Sprung);
Haemek Medical Center (A Lev); Kaplan Medical Center
(E Kishinevsky); Rabin Medical Center (J Cohen); Soroka
Medical Center (S Sofer) Italy: A.O Niguarda (S Vesconi);
A.O. Ospedale Di Circolo Di Busto Arsizio (S Greco);
A.O. Treviglio-Caravaggio (M Borelli); Anestesia E
Rianimazione 2 Prof.De Gaudio (P Cecilia); Arnas Ospedale
Civico (M Sapuppo); ASL 10 (A Lazzero); ASL 10 Florence
Hospital San Giovanni Di Dio (V Mangani); Azienda
Ospedaliera Desenzano (N Petrucci); Azienda Ospedaliera
Di Melegnano (M Minerva); Azienda Ospedaliera G.
Rummo (E De blasio); Azienda Ospedaliera Polo Univer-
sitario San Paolo (S Marzorati); Azienda Ospedaliera
Santa Maria Alle Scotte (R Rosi); Azienda Ospedaliera
Universitaria P.Giaccone Policlinico (A Giarratano);
Azienda Ospedaliera-Universitaria Udine (O Margarit);
Azienda Ospedaliero -Universitaria (A Guberti); Azienda
Ospedaliero-Universitaria S.M.Misericordia (S Scolz);
Clinica San Gaudenzio (E Stelian); Fondazione IRCCS
Policlinico San Matteo (V Emmi); Fondazione Ospedale
Maggiore Policlinico, Mangiagalli Regina Elena (M
Caspani); Fondazione Poliambulanza (A Rosano); H San
Gerardo (C Abbruzzese); Hospital Panico Tricase (S
Colonna); Humanitas Gavazzeni (R Ceriani); II Faculty of
Medicne I University of Rome- Osp. S.Andrea (R De Blasi);
S. Salvatore Hospital (L Panella); IRCCS Casa Sollievo Della
Sofferenza (F Borrelli); Istituto Nazionale Tumori Regina
Elena (P Lorella); KH Brixen (H Ruatti); Osepdali Riuniti Di
Ancona (C Munch); Ospedale "Ca Foncello" - Treviso
(Italia) (C Sorbara); Ospedale "Santa Croce" - ASL 8
(G Fiore); Ospedale Bufalini-Cesena (A Chieregato);
Ospedale Di Circolo E Fondazione Macchi (V Conti);
Ospedale Di Massa (A Guadagnucci); Azienda USL
Piacenza (M Pizzamiglio); Ospedale Ferrarotto (M Locicero);
Ospedale Maggiore Ausl Bologna (I Marri); Ospedale
Maggiore Policlinico Milano (A Sicignano); Ospedale
Maggiore Policlinico, Mangiagalli E Regina Elena,
IRCCS Milano (V Conte); Ospedale Mugello Azienda
Sanitaria Firenze (R Oggioni); Ospedale Niguarda Ca
Granda, Milano (A De Gasperi); IRCCS Centro di Riferimento
Oncologico della Basilicata (P De Negri); Ospedale
Provinciale Pistoia (G Santagostino); Ospedale S. Gerardo
(R Fumagalli); Ospedale San Raffaele (G Marino); Ospedele
Vittorio Emanuele (G Castiglione); P.O. San Severo Asl Fg
(D Sforza); S. Camillo Hospitql (N Giuseppe); San
Martino Hospital (M Bassetti); Seconda Università
Degli Studi Di Napoli (F Ferraro); Sesto San Giovanni
Hospital (S Clementi); Teaching Hospital Careggi (D
Alessandro); Terapia Intensiva - Aso S. Giovanni Battista
Di Torino - Ospedale Molinette (P Cotogni, MV Ranieri);
Università Cattolica (M Antonelli); Universita' Cattolica
Del S. Cuore (L Martinelli); University-Hospital Careggi,
Florence, (L Gianesello); University Hospital Policlinico Di
Catania (A Gullo); University of Rome "La Sapienza" (A
Morelli); UTI Trapianti (G Biancofiore); University of
Udine (G Della Rocca) Malta: St Luke’s Hospital (M
Borg); Netherlands: Academic Medical Center (A De Pont);
Amphia Hospital (P Rosseel); Antoni Van Leeuwenhoek
Ziekenhuis (J Ten Cate); Beatrix Zienhuis Rivas Zorggroep
(G Van Berkel); Canisius Wilhelmina Ziekenhuis (S
Corsten); Erasmus Mc University Medical Center (J
Bakker); Hagaziekenhuis (J Vogelaar); Hofpoort Hos-
pital Woerden (H Blom); Isala Clinics (H Kieft); Medical
Center Leeuwarden (M Kuiper); Medisch Spectrum
Twente (A Gille); Radboud University Nijmegen Med-
ical Centre (P Pickkers); Rode Kruis Ziekenhuis (J Vet);
Slingeland Ziekenhuis (J Ammann); Spaarneziekenhuis
(S Den Boer); St. Antonius Ziekenhuis (R Wesselink);
St.Elisabeth Hospital (B Speelberg); Twenteborg Hos-
pital Almelo (C Pham); University Medical Center,
Groningen (M Rodgers); University Hospital Maastricht (D
Bergmans); Vu University Medical Center (J Groeneveld);
Norway: Aker University Hospital (R Loevstad); St Olavs
University Hospital (P Klepstad); Sykehuset Asker Og
Bærum Hf (P Erno); Sykehuset I Vestfold Hf, Toensberg (A
Junker); Portugal: Centro Hospitalar Alto Ave (A Bártolo);
Centro Hospitalar Cova Da Beira (M Castelo-Branco
Sousa); Centro Hospitalar Trás os Montes e Alto
Douro (F Esteves); CHLO-Hospital S Francisco Xavier (A
Martins); H S João (T Oliveira); Hospital CUF Infante
Santo (P Ponce); Hospital Curry Cabral (L Mourão); Hos-
pital da Luz (C Febra); Hospital de Egas Moniz (E Carmo);
Hospital de S. José (V Lopes); Hospital de São Francisco
Xavier (P Póvoa); Hospital de São José (A Rezende); Hos-
pital Divino Espirito Santo (H Costa); Hospital do Litoral
Alentejano (P Moreira); Hospital Dr. José Maria Grande,
Portalegre (F Pádua); Hospital Fernando Fonseca (A
Leite); Hospital Garcia de Orta (E Almeida); Hospital
Geral de Santo António (M Alves); Hospital de Pulido
Valente (A Sousa, L Telo); Hospital de S. João (C Dias,
J Paiva); Hospital de São Bernardo (R Ribeiro); Hos-
pital de São Sebastião, EPE (P Amaro); Hospital Geral
de Sto Antánio (A Carneiro); Hospital de St. António dos
Capuchos (R Moreno, Ricardo Matos, Susana Afonso);
Instituto Português de Oncologia de Lisboa (M Bouw);
Hospital de St Maria (C França); Spain: Althaia (O Rubio);
Bellvitge University Hospital (R Mañez); Centro Medico
Delfos (M Burgueño Campiñez); Clinica Moncloa (M
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Alvarez); Clinica Rotger (R Jorda); Clinica Santa Elena (E
Naveira-Abeigón); Clinica Universitaria de Navarra
(P Monedero); Complejo Hospitalario de Pontevedra (E
Alemparte-Pardavila); Fundacion Hospital Alcorcon (S
Garcia del Valle); Fundacion Jimenez Diaz (C Perez Calvo);
H Vall Hebron (M Palomar); H.U. Virgen de Las Nieves- H.
Traumatología Y Rehabilitación (F Guerrero); Hospital
"Virgen de La Concha" - Zamora (A Caballero Zirena);
Hospital Arnau de Vilanova (M Arribas); Hospital Can
Misses (E Bustamante Munguira); Hospital Casa de Salud (J
Ruiz); Hospital Central de Asturias (L Iglesias); Hospital
Clinic (E Zavala); Hospital Clinic de Barcelona (M Valencia);
Hospital Clinico San Carlos (A Blesa Malpica); Hospital
Clinico San Carlos (F Martinez-Sagasti, M Nieto); Hospital
Clinico Universitario (G Aguilar); Hospital Clinico Univer-
sitario de Santiago (F Martinon-Torres); Hospital Comarcal
Vinaros (C Lorente); Hospital de Navarra (J Insausti);
Hospital de Antequera (R Vegas Pinto); Hospital de Basurto
(I Santos); Hospital de Fuenlabrada (A Escriba); Hospital de
Galdakao (P Olaechea); Hospital de La Merced (E Muñoz);
Hospital de Manacor (E Antón Caraballo); Hospital de
Mostoles (P Galdos-Anuncibay); Hospital de Sagunto
(V Lopez Camps); Hospital de Tortosa Verge de La
Cinta (F Esteban-Reboll); Hospital del Sas de Jerez (A
Estella); Hospital Donostia (L Bocero); Hospital Dr
Peset (A Ibañez); Hospital G. Yagüe (L Pueyo); Hospital
General (L María Jesús); Hospital General de Asturias (L
Iglesias); Hospital General de Ciudad Real (J Silva); Hos-
pital General de Granollers (P Garro); Hospital General de
La Palma (L Ramos-gómez); Hospital General de L'Hospita-
let (A Rovira); Hospital General de Vic (M Martin Delgado);
Hospital General Salud "Obispo Polanco" (J Monton Dito);
Hospital General Universitario de Albacete (F Garcia); Hos-
pital General Universitario de Alicante (J Navarro); Hospital
General Universitario de Elche (J Latour-Perez); Hospital
General Universitario de Guadalajara (A Albaya); Hospital
General Universitario Gregorio Marañon (A Bustinza); Hos-
pital Gran Canaria "Dr Negrín" (J Sole-violán); Hospital
Marques de Valdecilla (P Ugarte Peña); Hospital Maz (I
Yuste); Hospital Parque San Antonio (J De Rojas Román);
Hospital Sabadell (J Vallés); Hospital Sant Joan de Déu (E
Esteban); Hospital Sant Pau (E Quintana Tort-Martorell);
Hospital Santa María del Rosell (M Moreno); Hospital Santa
Maria Madre-Complejo Hospitalario de Ourense (V López
Ciudad); Hospital Santiago Apostol (A Manzano Ramirez);
Hospital Sevilla-Aljarafe (J Sánchez-Olmedo); Hospital Son
Llàtzer (M Borges); Hospital Terrassa (J Amador Amerigo);
Hospital Torrecardenas (F Guerrero Gomez); Hospital Uni-
versitaio 12 de Octubre (J Montejo González); Hospital
Universitari de Girona Doctor Josep Trueta (J Sirvent);
Hospital Universitari Germans Trias I Pujol (E Mesalles
Sanjuan); Hospital Universitario Arnau de Vilanova (F
Barcenilla-Gaite); Hospital Universitario de Canarias (N
Serrano); Hospital Universitario de Getafe (E Cerdá);
Hospital Universitario de Valme (A Lesmes Serrano);
Hospital Universitario Doce de Octubre (C Garcia-
Fuentes); Hospital Universitario Infanta Crsitina (J Macias
Pingarrón); Hospital Universitario Nªsra de Candelaria (E
Espinosa); Hospital Universitario Principe de Asturias (M
Sanchez Garcia); Hospital Universitario Reina Sofía, Murcia
(F Felices); Hospital Universitario Virgen de La Victoria (M
de la Torre-Prados); Hospital Univesitario Puerto Real (H
Maria Jesus); Hospital Valle del Nalon (V Luis); Hospital Vir-
gen Arrixaca (R Jara); Hospital Xanit Internacional (M
Briones Lopez); Hospital Xeral Cies (P Posada); Hu La Paz
(B Galvan); Hu La Paz (F Mariscal); Joan Xxiii University
Hospital (J Rello); Morales Meseguer (B Gil); Puerta del Mar
Universitary Hospital (R Sierra); Rio Hortega University Hos-
pital (J Rico-Feijoo); San Pedro de Alcantara Hospital (C
Corcobado Márquez); Servicio Navarro de Salud.Hospital
Virgen del Camino (J Izura); Uci H. U. Salamanca (J
González); Universitary Hospital Dr. Peset (J Soto Ibáñez);
Sweden: Anestesikliniken (P Petersen); Centralsjukhuset
Karlstad (L Johansson); University Hospital, Linköping (H
Blomqvist, B Peterzén, N Wyon); Göteborg (I Lindström);
Kärnsjukhuset Skövde (A Paulsson); Karolinska University
Hospital Huddinge (C Agvald-Ohman); Karolinska Univer-
sity Hospital, Solna (J Petersson); Lund University Hospital
(H Friberg); Malmoe University Hospital (V Einar); Op/Iva
Kliniken (F Hammarskjöld); Ostersund Hospital (M
Schindele); Ostra Hospital, Göteborg (S Arvidsson);
Sahlgrenska University Hospital (J Sellgren); Söder Hospital
(Södersjukhuset) (J Hulting); Sodersjukhuset (J Häggqvist);
Sollefteå Hospital (J Rudenstam); Sunderby Hospital (D
Lind); The Queen Silvia Children’s Hospital (E Kokinsky);
Thoracic Intensive Care, Karolinska Hospital (A Owall);
Umeå University Hospital (S Jacobson); University Hospital
(H Stiernstrom); University Hospital of Örebro (A Nydahl);
Turkey: Acibadem Kadikoy Hospital (K Atalan); Acibadem
Bakirkoy Hospital (C Ates); Acibadem Bursa Hospital (A
Kahveci); Acibadem Kozyatagi Hospital (H Fistikci); Ankara
Univercity (A Kaya); Ankara University Medical Faculty,
Ibni Sina Hospital (E Ozgencil); Ataturk University Medical
Faculty (M Kizilkaya); Dicle University Medical School (M
Bosnak); Dokuz Eylul University (H Bodur); Dokuz Eylul
University School of Medicine (M Akan); Erciyes University
Medical Faculty (M Guven); Gazi University School of
Medicine (M Turkoglu); Hacettepe University Hospital (A
Topeli); Inonu University Medical Faculty (T Togal);
Istanbul Faculty of Medicine (N Uzel); Istanbul Medical
Faculty (I Akinci, N Cakar, S Tugrul); Istanbul Univer-
sity Cerrahpasa Medical School (O Demirkiran); Izmir
Ataturk Training and Resarch Hospital (T Adanir); Memor-
ial Hospital (K Dogruer); Okmeydani Teaching & Research
Hospital (A Turkmen); Okmeydani Teaching & Research
Hospital (H Guven); Ondokuz Mayis University, Medical
Faculty (F Ulger); Selcuk University Meram Faculty of
Medicine (S Kocak).
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